{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:40:00Z","timestamp":1783381200241,"version":"3.54.6"},"reference-count":24,"publisher":"Frontiers Media SA","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transpl Int"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1111\/tri.12718","type":"journal-article","created":{"date-parts":[[2015,11,17]],"date-time":"2015-11-17T15:24:43Z","timestamp":1447773883000},"page":"315-322","source":"Crossref","is-referenced-by-count":24,"title":["Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and\/or viremia"],"prefix":"10.3389","volume":"29","author":[{"given":"Julie","family":"Belliere","sequence":"first","affiliation":[{"name":"Department of Nephrology and Organ Transplantation; University Hospital; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Kamar","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Organ Transplantation; University Hospital; Toulouse France"},{"name":"INSERM U563; IFR-BMT; CHU Purpan; Toulouse France"},{"name":"University Paul Sabatier; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Mengelle","sequence":"additional","affiliation":[{"name":"INSERM U563; IFR-BMT; CHU Purpan; Toulouse France"},{"name":"Department of Virology; CHU Purpan; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Allal","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Organ Transplantation; University Hospital; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Sallusto","sequence":"additional","affiliation":[{"name":"Department of Urology and Kidney Transplantation; CHU Rangueil; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Doumerc","sequence":"additional","affiliation":[{"name":"Department of Urology and Kidney Transplantation; CHU Rangueil; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Game","sequence":"additional","affiliation":[{"name":"Department of Urology and Kidney Transplantation; CHU Rangueil; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Congy-Jolivet","sequence":"additional","affiliation":[{"name":"University Paul Sabatier; Toulouse France"},{"name":"Laboratory of Immunology; CHU Rangueil; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Organ Transplantation; University Hospital; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Debiol","sequence":"additional","affiliation":[{"name":"Etablissement Fran\u00e7ais du Sang; CHU Purpan; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Rostaing","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Organ Transplantation; University Hospital; Toulouse France"},{"name":"INSERM U563; IFR-BMT; CHU Purpan; Toulouse France"},{"name":"University Paul Sabatier; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2015,12,16]]},"reference":[{"key":"10.1111\/tri.12718-BIB0001|tri12718-cit-0001","first-page":"307","article-title":"ABO-incompatible kidney transplantation: long-term outcomes","author":"Tanabe","year":"2013","journal-title":"Clin Transpl"},{"key":"10.1111\/tri.12718-BIB0002|tri12718-cit-0002","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1093\/ndt\/gfr215","article-title":"Increase of infectious complications in ABO-incompatible kidney transplant recipients-a single centre experience","volume":"26","author":"Habicht","year":"2011","journal-title":"Nephrol Dial Transpl"},{"key":"10.1111\/tri.12718-BIB0003|tri12718-cit-0003","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.4049\/jimmunol.153.7.3307","article-title":"Rapamycin inhibits production of cytotoxic but not noncytotoxic antibodies and preferentially activates T helper 2 cells that mediate long-term survival of heart allografts in rats","volume":"153","author":"Ferraresso","year":"1994","journal-title":"J Immunol"},{"key":"10.1111\/tri.12718-BIB0004|tri12718-cit-0004","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1093\/ndt\/gfq230","article-title":"Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat","volume":"25","author":"Vogelbacher","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/tri.12718-BIB0005|tri12718-cit-0005","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":"Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation","volume":"25","author":"Langer","year":"2012","journal-title":"Transpl Int"},{"key":"10.1111\/tri.12718-BIB0006|tri12718-cit-0006","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.trre.2013.06.001","article-title":"Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation","volume":"27","author":"Peddi","year":"2013","journal-title":"Transpl Rev"},{"key":"10.1111\/tri.12718-BIB0007|tri12718-cit-0007","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.bcp.2008.12.009","article-title":"Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12","volume":"77","author":"Van Rossum","year":"2009","journal-title":"Biochem Pharmacol"},{"issue":"Suppl 4","key":"10.1111\/tri.12718-BIB0008|tri12718-cit-0008","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/ajt.12110","article-title":"BK polyomavirus in solid organ transplantation","volume":"13","author":"Hirsch","year":"2013","journal-title":"Am J Transpl"},{"key":"10.1111\/tri.12718-BIB0009|tri12718-cit-0009","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/rmv.1733","article-title":"Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms","volume":"23","author":"Brennan","year":"2013","journal-title":"Rev Med Virol"},{"key":"10.1111\/tri.12718-BIB0010|tri12718-cit-0010","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2215\/CJN.00770112","article-title":"Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients","volume":"7","author":"Sharif","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1111\/tri.12718-BIB0011|tri12718-cit-0011","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/tid.12347","article-title":"Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients","volume":"17","author":"Tohme","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1111\/tri.12718-BIB0012|tri12718-cit-0012","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/ctr.12151","article-title":"Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience","volume":"27","author":"Moscarelli","year":"2013","journal-title":"Clin Transpl"},{"key":"10.1111\/tri.12718-BIB0013|tri12718-cit-0013","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.transproceed.2008.05.047","article-title":"Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure","volume":"40","author":"Carmellini","year":"2008","journal-title":"Transpl Proc"},{"key":"10.1111\/tri.12718-BIB0014|tri12718-cit-0014","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1016\/j.transproceed.2010.08.043","article-title":"Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy","volume":"42","author":"Kacar","year":"2010","journal-title":"Transpl Proc"},{"key":"10.1111\/tri.12718-BIB0015|tri12718-cit-0015","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1111\/tri.12304","article-title":"Everolimus-based immunosuppression in a case of ABO-incompatible liver transplantation with calcineurin inhibitor-related posterior occipital syndrome","volume":"27","author":"Catalano","year":"2014","journal-title":"Transpl Int"},{"key":"10.1111\/tri.12718-BIB0016|tri12718-cit-0016","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/ctr.12281","article-title":"Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study","volume":"28","author":"Uchida","year":"2013","journal-title":"Clin Transpl"},{"key":"10.1111\/tri.12718-BIB0017|tri12718-cit-0017","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1600-6143.2011.03961.x","article-title":"Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation","volume":"12","author":"Liefeldt","year":"2012","journal-title":"Am J Transpl"},{"key":"10.1111\/tri.12718-BIB0018|tri12718-cit-0018","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/TP.0b013e3182848e03","article-title":"Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation","volume":"95","author":"Cibrik","year":"2013","journal-title":"Transplantation"},{"key":"10.1111\/tri.12718-BIB0019|tri12718-cit-0019","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1097\/TP.0b013e318216c1db","article-title":"Everolimus and minimization of cyclosporine in renal transplantation: 24-month follow-up of the EVEREST study","volume":"91","author":"Ponticelli","year":"2011","journal-title":"Transplantation"},{"key":"10.1111\/tri.12718-BIB0020|tri12718-cit-0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ajt.12952","article-title":"Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study","volume":"15","author":"Budde","year":"2015","journal-title":"Am J Transpl"},{"key":"10.1111\/tri.12718-BIB0021|tri12718-cit-0021","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/TP.0000000000000225","article-title":"Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients","volume":"99","author":"Oh","year":"2015","journal-title":"Transplantation"},{"key":"10.1111\/tri.12718-BIB0022|tri12718-cit-0022","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/ctr.12418","article-title":"Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors","volume":"28","author":"Perbos","year":"2014","journal-title":"Clin Transpl"},{"key":"10.1111\/tri.12718-BIB0023|tri12718-cit-0023","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1111\/ajt.12852","article-title":"Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis","volume":"14","author":"Murakami","year":"2014","journal-title":"Am J Transpl"},{"key":"10.1111\/tri.12718-BIB0024|tri12718-cit-0024","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.transproceed.2013.01.026","article-title":"The risk of polyomavirus-associated graft nephropathy is increased by a combined suppression of CD8 and CD4 cell-dependent immune effects","volume":"45","author":"Renner","year":"2013","journal-title":"Transpl Proc"}],"container-title":["Transplant International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftri.12718","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/tri.12718\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T21:56:46Z","timestamp":1692136606000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tri.12718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,16]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"URL":"https:\/\/doi.org\/10.1111\/tri.12718","archive":["Portico"],"relation":{},"ISSN":["0934-0874"],"issn-type":[{"value":"0934-0874","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12,16]]}}}